Aline Cristiane Planello
Research Subjects
Aline Cristiane Planello has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Darine Villela
Diagnósticos da América S.A., DASA São Paulo Brazil
2 shared publications - Thereza Loureiro
Diagnósticos da América S.A., Brazil
2 shared publications Ana Paula de Souza
Department of Biosciences Faculdade de Odontologia de Piracicaba/Universidade de Campinas (UNICAMP) Brazil
1 shared publicationBeatriz Cantieri Almeida
Jundiaí Medical School (FMJ), Jundiaí, SP, Brazil
1 shared publicationBeatriz Gafanhão Bobadilha
Department of Morphology and Basic Pathology - Medical School, Faculdade de Medicina de Jundiaí
1 shared publicationBeatriz Meza Baraldi
Department of Morphology & Basic Pathology – Medical School, Faculdade de Medicina de Jundiaí, Jundiaí, 13202-550, Brazil
1 shared publication
Latest Publications
- Open Access
- 23 July 2026
- Published by Wiley in FEBS Open Bio
- Vol. 16 (11) , 2141-2152
Dual native G‐quadruplex folding is associated with chromatin looping at the MYC locus
DNA can adopt noncanonical four‐stranded structures known as G‐quadruplexes (G4s), which are enriched at regulatory regions and implicated in transcriptional control. However, the process by which native G4 folding contributes to enhancer–promoter communication and three‐dimensional genome organization remains poorly understood. Here, we investigated the relationship between G4 folding, chromatin state and long‐range regulatory interactions by integrating chromatin state maps, DNA methylation profiles, and BG4 ChIP‐seq data across two closely related human keratinocyte models. To assess long‐range regulatory contacts directly, we applied locus‐specific chromosome conformation capture (3C‐qPCR) at endogenous regulatory loci. Genome‐wide analyses revealed that both folded and unfolded G4 loci, operationally defined by BG4 detection, are enriched at transcription start sites and active enhancer regions. However, unfolded G4s preferentially associate with weak enhancers, consistent with a poised regulatory state. Focusing on the endogenous MYC – PVT1 locus, enhancer–promoter contacts were detectable only in the cellular context where folded G4s were present at both the promoter and distal enhancers, independently of active histone marks alone. Together, these findings position this dual G4 folding as a genomic feature associated with enhancer–promoter communication and three‐dimensional regulatory architecture.
- 23 July 2026
- Published by Wiley in FEBS Open Bio
- Vol. 16 (11) , 2141-2152
Open AccessDual native G‐quadruplex folding is associated with chromatin looping at the MYC locus
DNA can adopt noncanonical four‐stranded structures known as G‐quadruplexes (G4s), which are enriched at regulatory regions and implicated in transcriptional control. However, the process by which native G4 folding contributes to enhancer–promoter communication and three‐dimensional genome organization remains poorly understood. Here, we investigated the relationship between G4 folding, chromatin state and long‐range regulatory interactions by integrating chromatin state maps, DNA methylation profiles, and BG4 ChIP‐seq data across two closely related human keratinocyte models. To assess long‐range regulatory contacts directly, we applied locus‐specific chromosome conformation capture (3C‐qPCR) at endogenous regulatory loci. Genome‐wide analyses revealed that both folded and unfolded G4 loci, operationally defined by BG4 detection, are enriched at transcription start sites and active enhancer regions. However, unfolded G4s preferentially associate with weak enhancers, consistent with a poised regulatory state. Focusing on the endogenous MYC – PVT1 locus, enhancer–promoter contacts were detectable only in the cellular context where folded G4s were present at both the promoter and distal enhancers, independently of active histone marks alone. Together, these findings position this dual G4 folding as a genomic feature associated with enhancer–promoter communication and three‐dimensional regulatory architecture.
- Open Access
- 9 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17
Pharmacogenomics of risperidone in autism spectrum disorder: a minireview
Risperidone is one of the most widely prescribed antipsychotics for the management of irritability and associated behavioral symptoms in autism spectrum disorder (ASD), yet clinical response and adverse-effect risk vary widely among individuals. Pharmacogenomic (PGx) research has sought to explain this variability, with accumulating evidence pointing to contributions from metabolic, transporter, and neurotransmitter pathways. In this narrative minireview, we synthesize current findings on PGx factors influencing risperidone outcomes in children and adolescents with ASD. CYP2D6 emerges as the most robust predictor of pharmacokinetics and toxicity, while pharmacodynamic associations involving dopaminergic, serotonergic, and metabolic pathways in genes such as ABCB1 , DRD3 , HTR2A , HTR2C , and LEP remain inconsistent and largely derived from small cohorts. We also discuss methodological challenges in assessing treatment response, current clinical guidelines, barriers to implementation, and emerging approaches including polygenic models, pharmacoepigenomics, and machine learning. Together, the available evidence points to both the promise and the limitations of PGx in guiding safer and more individualized risperidone therapy in ASD.
- 9 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17
Open AccessPharmacogenomics of risperidone in autism spectrum disorder: a minireview
Risperidone is one of the most widely prescribed antipsychotics for the management of irritability and associated behavioral symptoms in autism spectrum disorder (ASD), yet clinical response and adverse-effect risk vary widely among individuals. Pharmacogenomic (PGx) research has sought to explain this variability, with accumulating evidence pointing to contributions from metabolic, transporter, and neurotransmitter pathways. In this narrative minireview, we synthesize current findings on PGx factors influencing risperidone outcomes in children and adolescents with ASD. CYP2D6 emerges as the most robust predictor of pharmacokinetics and toxicity, while pharmacodynamic associations involving dopaminergic, serotonergic, and metabolic pathways in genes such as ABCB1 , DRD3 , HTR2A , HTR2C , and LEP remain inconsistent and largely derived from small cohorts. We also discuss methodological challenges in assessing treatment response, current clinical guidelines, barriers to implementation, and emerging approaches including polygenic models, pharmacoepigenomics, and machine learning. Together, the available evidence points to both the promise and the limitations of PGx in guiding safer and more individualized risperidone therapy in ASD.
- 3 September 2025
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 300 (1) , 1-11
Variant classification of hereditary cancer genes is affected by genomic underrepresentation of admixed populations
Variant classification in genetic testing often culminates in “uncertain” calls, known as variants of uncertain significance (VUS), which remain a major clinical challenge. Among the established criteria for variant classification, population allele frequency (AF) is fundamental, yet under-representation of non-European groups hinders accurate interpretation. In this study, we evaluated the impact of population-specific AF on the reclassification of VUS and conflicting variants in hereditary cancer genes. From ClinVar, we curated 487 variants present in both the Brazilian cohort ABraOM and gnomAD v4.1 databases. Comparative population analysis revealed that 43% of shared variants showed significantly different AFs (q ≤ 0.01), with 113 (23%) exhibiting large effect sizes (OR ≥ 4), including 39 VUS. Among these, 20 VUS had higher AF in the Brazilian cohort and exceeded benignity thresholds (BS1), while remaining rare in other populations. Functional prediction tools such as REVEL and CADD failed to distinguish these variants from globally rare VUS. Integrating Brazilian‑specific AF with ClinGen VCEP rules downgraded 15% (3/20) of candidate VUS and resolved five conflicting calls. These findings argue for routine incorporation of regional reference datasets in diagnostic curation to reduce uncertainty and avoid inappropriate clinical management in diverse populations.
- 3 September 2025
- Published by Springer Nature in Molecular Genetics and Genomics
- Vol. 300 (1) , 1-11
Variant classification of hereditary cancer genes is affected by genomic underrepresentation of admixed populations
Variant classification in genetic testing often culminates in “uncertain” calls, known as variants of uncertain significance (VUS), which remain a major clinical challenge. Among the established criteria for variant classification, population allele frequency (AF) is fundamental, yet under-representation of non-European groups hinders accurate interpretation. In this study, we evaluated the impact of population-specific AF on the reclassification of VUS and conflicting variants in hereditary cancer genes. From ClinVar, we curated 487 variants present in both the Brazilian cohort ABraOM and gnomAD v4.1 databases. Comparative population analysis revealed that 43% of shared variants showed significantly different AFs (q ≤ 0.01), with 113 (23%) exhibiting large effect sizes (OR ≥ 4), including 39 VUS. Among these, 20 VUS had higher AF in the Brazilian cohort and exceeded benignity thresholds (BS1), while remaining rare in other populations. Functional prediction tools such as REVEL and CADD failed to distinguish these variants from globally rare VUS. Integrating Brazilian‑specific AF with ClinGen VCEP rules downgraded 15% (3/20) of candidate VUS and resolved five conflicting calls. These findings argue for routine incorporation of regional reference datasets in diagnostic curation to reduce uncertainty and avoid inappropriate clinical management in diverse populations.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (7) , e20250086
Assessing the impact of exome sequencing on diagnostic yield in a large cohort of Brazilian patients
SUMMARY OBJECTIVE: This study aimed to evaluate whether the increased use of exome sequencing as a primary next-generation sequencing test provides a higher diagnostic yield compared to multi-gene panels for various clinical indications within a Brazilian cohort. METHODS: We retrospectively analyzed test results from 3,025 patients who underwent single-gene tests, multi-gene panels, and exome sequencing in our laboratory. The results were categorized as positive, inconclusive, or negative, with clinical indications including neurodevelopmental, late-onset neurological, neuromuscular, syndromic, skin/hair, hematological/immunologic, ophthalmologic, inborn errors of metabolism, skeletal, cardiovascular, reproductive planning, cancer, genitourinary, gastrointestinal, and hearing disorders. RESULTS: Of the 3,025 next-generation sequencing-based tests, 420 were single-gene tests, 1,158 were multi-gene panels, and 1,447 were exome sequencing. Although multi-gene panels were initially the most frequently ordered test, exome sequencing currently represents 62% of all next-generation sequencing-based tests performed in our laboratory. Exome sequencing had the highest detection rate (32.7%), but also the highest inconclusive rate. Among the clinical indications, when stratified by exome sequencing, skeletal and hearing disorders had the highest diagnostic yield, corresponding to 55 and 50%, respectively. CONCLUSION: This study emphasizes the diagnostic usefulness of exome sequencing for complex genetic disorders in postnatal diagnosis. However, the expansion of exome sequencing also presents challenges, including an increased rate of inconclusive results due to variants of uncertain significance. Broader availability of exome sequencing must be accompanied by additional resources to address these challenges effectively.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (7) , e20250086
Open AccessAssessing the impact of exome sequencing on diagnostic yield in a large cohort of Brazilian patients
SUMMARY OBJECTIVE: This study aimed to evaluate whether the increased use of exome sequencing as a primary next-generation sequencing test provides a higher diagnostic yield compared to multi-gene panels for various clinical indications within a Brazilian cohort. METHODS: We retrospectively analyzed test results from 3,025 patients who underwent single-gene tests, multi-gene panels, and exome sequencing in our laboratory. The results were categorized as positive, inconclusive, or negative, with clinical indications including neurodevelopmental, late-onset neurological, neuromuscular, syndromic, skin/hair, hematological/immunologic, ophthalmologic, inborn errors of metabolism, skeletal, cardiovascular, reproductive planning, cancer, genitourinary, gastrointestinal, and hearing disorders. RESULTS: Of the 3,025 next-generation sequencing-based tests, 420 were single-gene tests, 1,158 were multi-gene panels, and 1,447 were exome sequencing. Although multi-gene panels were initially the most frequently ordered test, exome sequencing currently represents 62% of all next-generation sequencing-based tests performed in our laboratory. Exome sequencing had the highest detection rate (32.7%), but also the highest inconclusive rate. Among the clinical indications, when stratified by exome sequencing, skeletal and hearing disorders had the highest diagnostic yield, corresponding to 55 and 50%, respectively. CONCLUSION: This study emphasizes the diagnostic usefulness of exome sequencing for complex genetic disorders in postnatal diagnosis. However, the expansion of exome sequencing also presents challenges, including an increased rate of inconclusive results due to variants of uncertain significance. Broader availability of exome sequencing must be accompanied by additional resources to address these challenges effectively.
- 30 January 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (2) , 69-78
Psychiatric Level 1A Evidence Pharmacogenomics in a Brazilian Admixed Cohort and Global Populations
Purpose: To compare minor allele frequencies (MAFs) of psychiatric drug response variants in a Brazilian admixed cohort with global populations and other Brazilian groups. Methods: PharmGKB MAFs we...
- 30 January 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (2) , 69-78
Psychiatric Level 1A Evidence Pharmacogenomics in a Brazilian Admixed Cohort and Global Populations
Purpose: To compare minor allele frequencies (MAFs) of psychiatric drug response variants in a Brazilian admixed cohort with global populations and other Brazilian groups. Methods: PharmGKB MAFs we...
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (6) , e20240215
MTHFR genetic testing: is there a clinical utility?
The MTHFR genetic testing investigates two common variants, 677C>T and 1298A>C, and is frequently ordered by several providers due to the association of those variants with several multifactorial diseases, including cancer1 1 Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1632-42. https://doi.org/10.1158/1055-9965.EPI-10-0180 https://doi.org/10.1158/1055-9965.EPI-10... , autism2 2 Guo BQ, Li HB, Ding SB. Blood homocysteine levels in children with autism spectrum disorder: an updated systematic review and meta-analysis. Psychiatry Res. 2020;291:113283. , mental disorders3 3 Moradi F, Lotfi K, Armin M, Clark CCT, Askari G, Rouhani MH. The association between serum homocysteine and depression: a systematic review and meta-analysis of observational studies. Eur J Clin Invest. 2021;51(5):e13486. https://doi.org/10.1111/eci.13486 https://doi.org/10.1111/eci.13486... , cardiovascular diseases4 4 Chen A, Wu W, Gong J, Han Y, Xu G, Xie L. Association of homocysteine with carotid atherosclerosis in hypertension. J Hum Hypertens. 2023;37(3):227-34. https://doi.org/10.1038/s41371-022-00665-1 https://doi.org/10.1038/s41371-022-00665... , and congenital malformations5 5 Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle—biochemistry, pathways, and regulation. J Inherited Metab Dis. 2019;42:673-85. https://doi.org/10.1002/jimd.12009 https://doi.org/10.1002/jimd.12009... . The MTHFR gene encodes the enzyme methylenetetrahydrofolate reductase (MTFHR), which is a crucial component in the one-carbon metabolism pathway that involves folate and homocysteine. Genetic variants in the MTFHR may result in decreased enzyme activity, leading to alterations in homocysteine levels. However, it is not clear whether common variants are a major risk factor for diseases because their association with health conditions varies among different populations5 5 Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle—biochemistry, pathways, and regulation. J Inherited Metab Dis. 2019;42:673-85. https://doi.org/10.1002/jimd.12009 https://doi.org/10.1002/jimd.12009... ,6 6 Weile J, Kishore N, Sun S, Maaieh R, Verby M, Li R, et al. Shifting landscapes of human MTHFR missense-variant effects. Am J Hum Genet. 2021;108(7):1283-300. https://doi.org/10.1016/j.ajhg.2021.05.009 https://doi.org/10.1016/j.ajhg.2021.05.0... . Notably, some medical companies are currently offering routine MTHFR investigation as direct-to-consumer genetic testing. Although this type of testing is becoming increasingly popular due to its accessibility and affordability, it raises concerns about the accuracy of the results and the lack of proper genetic interpretation and counseling for individuals who receive positive results7 7 Martins MF, Murry LT, Telford L, Moriarty F. Direct-to-consumer genetic testing: an updated systematic review of healthcare professionals' knowledge and views, and ethical and legal concerns. Eur J Hum Genet. 2022;30(12):1331-43. https://doi.org/10.1038/s41431-022-01205-8 https://doi.org/10.1038/s41431-022-01205... . Several studies have demonstrated the complexity of translating research findings from genetic association studies of common variants in the clinical setting. The relationship between polymorphisms (i.e., common variants) and the risk for multifactorial diseases is complex and influenced by numerous aspects, including ancestry8 8 Crouch DJM, Bodmer WF. Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants. Proc Natl Acad Sci USA. 2020;117:18924-33. https://doi.org/10.1073/pnas.2005634117 https://doi.org/10.1073/pnas.2005634117... . Furthermore, interpreting polymorphisms, especially in admixed populations, as is the case of the Brazilian population, poses a significant challenge. In this article, we discuss why testing MTHFR polymorphisms needs caution, considering that it may not provide significant benefit to patients until more association studies are conducted in diverse populations and the effect of these variants on diseases is fully understood.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (6) , e20240215
Open AccessMTHFR genetic testing: is there a clinical utility?
The MTHFR genetic testing investigates two common variants, 677C>T and 1298A>C, and is frequently ordered by several providers due to the association of those variants with several multifactorial diseases, including cancer1 1 Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1632-42. https://doi.org/10.1158/1055-9965.EPI-10-0180 https://doi.org/10.1158/1055-9965.EPI-10... , autism2 2 Guo BQ, Li HB, Ding SB. Blood homocysteine levels in children with autism spectrum disorder: an updated systematic review and meta-analysis. Psychiatry Res. 2020;291:113283. , mental disorders3 3 Moradi F, Lotfi K, Armin M, Clark CCT, Askari G, Rouhani MH. The association between serum homocysteine and depression: a systematic review and meta-analysis of observational studies. Eur J Clin Invest. 2021;51(5):e13486. https://doi.org/10.1111/eci.13486 https://doi.org/10.1111/eci.13486... , cardiovascular diseases4 4 Chen A, Wu W, Gong J, Han Y, Xu G, Xie L. Association of homocysteine with carotid atherosclerosis in hypertension. J Hum Hypertens. 2023;37(3):227-34. https://doi.org/10.1038/s41371-022-00665-1 https://doi.org/10.1038/s41371-022-00665... , and congenital malformations5 5 Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle—biochemistry, pathways, and regulation. J Inherited Metab Dis. 2019;42:673-85. https://doi.org/10.1002/jimd.12009 https://doi.org/10.1002/jimd.12009... . The MTHFR gene encodes the enzyme methylenetetrahydrofolate reductase (MTFHR), which is a crucial component in the one-carbon metabolism pathway that involves folate and homocysteine. Genetic variants in the MTFHR may result in decreased enzyme activity, leading to alterations in homocysteine levels. However, it is not clear whether common variants are a major risk factor for diseases because their association with health conditions varies among different populations5 5 Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle—biochemistry, pathways, and regulation. J Inherited Metab Dis. 2019;42:673-85. https://doi.org/10.1002/jimd.12009 https://doi.org/10.1002/jimd.12009... ,6 6 Weile J, Kishore N, Sun S, Maaieh R, Verby M, Li R, et al. Shifting landscapes of human MTHFR missense-variant effects. Am J Hum Genet. 2021;108(7):1283-300. https://doi.org/10.1016/j.ajhg.2021.05.009 https://doi.org/10.1016/j.ajhg.2021.05.0... . Notably, some medical companies are currently offering routine MTHFR investigation as direct-to-consumer genetic testing. Although this type of testing is becoming increasingly popular due to its accessibility and affordability, it raises concerns about the accuracy of the results and the lack of proper genetic interpretation and counseling for individuals who receive positive results7 7 Martins MF, Murry LT, Telford L, Moriarty F. Direct-to-consumer genetic testing: an updated systematic review of healthcare professionals' knowledge and views, and ethical and legal concerns. Eur J Hum Genet. 2022;30(12):1331-43. https://doi.org/10.1038/s41431-022-01205-8 https://doi.org/10.1038/s41431-022-01205... . Several studies have demonstrated the complexity of translating research findings from genetic association studies of common variants in the clinical setting. The relationship between polymorphisms (i.e., common variants) and the risk for multifactorial diseases is complex and influenced by numerous aspects, including ancestry8 8 Crouch DJM, Bodmer WF. Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants. Proc Natl Acad Sci USA. 2020;117:18924-33. https://doi.org/10.1073/pnas.2005634117 https://doi.org/10.1073/pnas.2005634117... . Furthermore, interpreting polymorphisms, especially in admixed populations, as is the case of the Brazilian population, poses a significant challenge. In this article, we discuss why testing MTHFR polymorphisms needs caution, considering that it may not provide significant benefit to patients until more association studies are conducted in diverse populations and the effect of these variants on diseases is fully understood.
- 1 December 2021
- Published by Elsevier in Psychiatry Research
- Vol. 306, 114238
Perception and knowledge of pharmacogenetics among Brazilian psychiatrists
- 1 December 2021
- Published by Elsevier in Psychiatry Research
- Vol. 306, 114238
Perception and knowledge of pharmacogenetics among Brazilian psychiatrists